Paraganglioma

• CLINICAL_TRIALS trial_result · 2022-08-04
  Clinical Trial Update: First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma [Phase 2]

  A Phase 2 randomized international trial in malignant progressive pheochromocytoma and paraganglioma has completed.

• CLINICAL_TRIALS trial_result · 2021-11-24
  Clinical Trial Update: A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial [Phase 2]

  Phase II open-label single-arm study evaluating efficacy and safety of anlotinib in advanced or metastatic pheochromocytoma/paraganglioma.

• CLINICAL_TRIALS trial_result · 2021-05-14
  Clinical Trial Update: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery [Phase 2]

  Phase 2 clinical trial evaluating lenvatinib for metastatic or advanced pheochromocytoma or paraganglioma that cannot be surgically removed;…

• CLINICAL_TRIALS trial_result · 2021-05-10
  Clinical Trial Update: A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer [Phase 2]

  A Phase II trial of the DNA methyltransferase inhibitor guadecitabine (SGI-110) in children and adults with wild-type GIST, paraganglioma, p…

• CLINICAL_TRIALS trial_result · 2020-08-31
  Clinical Trial Update: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma [Phase 2]

  Phase II study evaluating axitinib (AG-013736) targeting VEGF pathway in metastatic/recurrent/unresectable pheochromocytoma and paragangliom…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2020-04-14
  Clinical Trial Update: Dovitinib in Neuroendocrine Tumors [Phase 2]

  Phase 2 trial of dovitinib in neuroendocrine tumors (paraganglioma and pheochromocytoma) completed.

• CLINICAL_TRIALS trial_result · 2019-11-12
  Clinical Trial Update: GA-68 DOTA-TOC of Somatostatin Positive Malignancies [Phase 1, Phase 2]

  Phase 1/2 clinical trial update for GA-68 DOTA-TOC targeting somatostatin receptors in neuroendocrine tumors and related malignancies, with …

• CLINICAL_TRIALS approval · 2019-01-30
  Clinical Trial Update: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

  Marketing approval for Ultratrace iobenguane I-131 has been granted for malignant relapsed/refractory pheochromocytoma and paraganglioma, pe…

• CLINICAL_TRIALS trial_result · 2018-10-05
  Clinical Trial Update: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma [Phase 2]

  Phase 2 study evaluating ultratrace Iobenguane I-131 in malignant relapsed/refractory pheochromocytoma and paraganglioma; results posted in …

• CLINICAL_TRIALS trial_result · 2018-09-18
  Clinical Trial Update: A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors [Phase 2]

  Phase II clinical trial evaluating 131I-Metaiodobenzylguanidine (MIBG) for metastatic or unresectable pheochromocytoma and related tumors ha…

• CLINICAL_TRIALS trial_result · 2017-01-19
  Clinical Trial Update: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors [Phase 2]

  Phase 2 trial of linsitinib in patients with gastrointestinal stromal tumors (and related conditions) has completed with results posted.

• CLINICAL_TRIALS trial_result · 2016-07-21
  Clinical Trial Update: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma [Phase 2]

  Phase 2 trial of pazopanib hydrochloride in advanced or progressive malignant pheochromocytoma or paraganglioma was terminated with results …

• CLINICAL_TRIALS trial_result · 2016-07-15
  Clinical Trial Update: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma [Phase 1]

  Phase 1 clinical trial evaluating the combination of Cixutumumab, Everolimus, and Octreotide acetate in patients with advanced low- to inter…

• CLINICAL_TRIALS trial_result · 2016-06-13
  Clinical Trial Update: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors [Phase 1]

  A Phase 1 trial evaluating the combination of temsirolimus and vinorelbine ditartrate in adults with unresectable or metastatic solid tumors…

• CLINICAL_TRIALS trial_result · 2016-04-20
  Clinical Trial Update: Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma [Phase 1, Phase 2]

  Phase 1/2 study of iobenguane I-131 (MIBG) in patients with malignant pheochromocytoma or paraganglioma completed; results were posted in 20…

• CLINICAL_TRIALS withdrawal · 2015-12-21
  Clinical Trial Update: Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma [Phase 1]

  The Phase I trial of vandetanib in combination with 131I-mIBG for advanced pheochromocytoma and paraganglioma has been withdrawn.

• CLINICAL_TRIALS trial_result · 2015-07-23
  Clinical Trial Update: Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers [NA]

  This completed clinical trial evaluated screening methods to detect tumors in SDH-positive carriers, addressing hereditary paraganglioma and…

• CLINICAL_TRIALS trial_result · 2015-05-20
  Clinical Trial Update: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid [Phase 2]

  A Phase 2 trial of RAD001 (everolimus) for pheochromocytoma, extra-adrenal paraganglioma, and non-functioning carcinoid has completed.

• CLINICAL_TRIALS trial_result · 2014-02-25
  Clinical Trial Update: Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot [NA]

  A completed pilot study assessing the feasibility of Iodine-123 IBZM scintigraphy as a diagnostic imaging tool in patients with pheochromocy…

• CLINICAL_TRIALS research · 2013-06-10
  Clinical Trial Update: Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma

  This trial update describes content validation of quality-of-life and symptom questionnaires for patients with pheochromocytoma and paragang…

• CLINICAL_TRIALS trial_result · 2011-10-12
  Clinical Trial Update: ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid [Phase 1]

  Phase 1 clinical trial of Ultratrace iobenguane I-131 in patients with malignant pheochromocytoma, paraganglioma, or metastatic carcinoid ha…

• CLINICAL_TRIALS trial_result · 2011-06-15
  Clinical Trial Update: 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors [Phase 3]

  This is a Phase 3 clinical trial update evaluating 123I‑MIBG scintigraphy for evaluating patients with suspected neuroendocrine tumors, incl…